Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opioid Growth Factor in Advanced Head and Neck Cancer
NCT00982696Phase 2Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Feb 2008
- Primary completion
- Nov 2011
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metenkephalin in head and neck squamous cell carcinoma (HNSCC), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Progression of tumor measured with CT scan. Started Feb 2008; status: terminated.
02
Drugs
metenkephalin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00982696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00982696.